Elsevier

Neuroscience Letters

Volume 615, 26 February 2016, Pages 88-91
Neuroscience Letters

Research paper
Val66Met BDNF polymorphism is associated with Parkinson's disease cognitive impairment

https://doi.org/10.1016/j.neulet.2016.01.030Get rights and content
Under an Elsevier user license
open access

Highlights

  • The role of BDNF VAL66Met in Parkinson's disease cognitive impairment was explored in this study.

  • BDNF 66Met allele presented a higher prevalence of cognitive impairment.

  • BDNF variability seems to be important for cognitive impairment in PD.

Abstract

Parkinson's disease (PD) is one of the most common neurodegenerative diseases worldwide. Besides characteristic PD motor features, the disease has important non-motor characteristics such as cognitive impairment. The role of genetic factors in cognitive impairment associated with PD is still unclear. In this study, we examined whether BDNF Val66Met was associated with impaired cognition in Parkinson's disease. One hundred and seventy five patients with a clinical diagnosis of Parkinson's disease were included. Global cognitive abilities of the patients were measured by the Mini-Mental State Examination (MMSE). Poisson Regression models were used to test for association between 66Met carriers and cognitive impairment controlling for covariates. Carriers of at least one BDNF 66Met allele presented a higher prevalence of cognitive impairment (p = 0.005 RR = 1.45 IC = 95% [1.1–1.8]). These results suggest a role for BDNF Val66Met polymorphism on cognitive impairment in PD.

Keywords

Parkinson's disease
BDNF
Cognitive impairment
Genetic susceptibility

Cited by (0)